TearLab reports interim results of dry eye study

Article

TearLab recently reported interim results of a multi-center dry eye disease (DED) prevalence study carried out in the UK at four National Health Service (NHS) hospitals.

San Diego, CA-TearLab recently reported interim results of a multi-center dry eye disease (DED) prevalence study carried out in the UK at four National Health Service (NHS) hospitals.

Assess dry eye from a systemic standpoint

The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. The study began in March and its interim phase was completed in June. The interim clinical trial results showed that osmolarity had the highest agreement with the International Dry Eye Workshop (DEWS) findings, which is a composite score based on several tests, and that traditional tests like staining and TBUT do not correlate well with the presence of the disease.

“The interim results of this study could have far-reaching consequences for the evaluation, diagnosis, and management of dry eye disease in the UK,” lead investigator and consultant ophthalmologist Francesca Harman, from Hillingdon Hospital, said in a statement.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
© 2025 MJH Life Sciences

All rights reserved.